8 results about "Medications therapy" patented technology

A computer-implemented method of estimating a risk associated with patient safety is disclosed. One or more computers execute processing comprising receiving a training data set comprising drug-associated patient safety data and human omics data. One or more probabilistic features from the training data set are identified, where the one or more probabilistic features comprise human omics features associated with a drug therapeutic. A ground truth label associated with the drug therapeutic and comprising a positive or a negative patient safety outcome corresponding to the one or more probabilistic features is derived. The method trains one or more machine learning models in accordance with the ground truth label and applies the trained machine learning models to a patient dataset of human omics data to generate a calculated indication of a positive or a negative patient safety outcome. The method takes one or more actions in response to the calculated indication.

A system and method of applying therapy to a patient includes navigating a dual lumen catheter to a desired segment of bronchus; inflating, via a first tube of the dual lumen catheter, a balloon located on a distal portion of the catheter to isolate the segment bronchial tube; injecting a therapeutic medium into the isolated segment bronchial tube via a second tube of the dual lumen catheter; and retracting the dual lumen catheter to leave the balloon indwelling, where the balloon retains the injected therapeutic medium in the isolated segment bronchial tube.

The application discloses application of a substance with increased OSKM content or activity in preventing joint cartilage aging and treating osteoarthritis diseases. The OSKM of the application is obtained by connecting Oct4, Sox2, Klf4 and C-Myc. The experiment of the application proves that the OSKM or the substance with increased OSKM content or activity has a definite effect in preventing joint cartilage aging and treating osteoarthritis diseases, the application provides a new strategy for developing gene therapy for preventing joint cartilage aging and treating osteoarthritis diseases, and expands the selectable range of clinical gene therapy and drug therapy.

The invention relates generally to medication therapy and more particularly to a system and methods for medication therapy management to support improved adherence and alert clinicians of changes in behavior or symptoms. The system may facilitate interactions between various data sources (e.g., medical health records, genomics databases, and other connected third-party devices) to manage workflow, execute rules, interface with knowledge bases, codify information, schedule events, provide notification, and more. In addition, the system may include a conversational or actionable artificial intelligence persona tailored to each user and configured to, for example, converse, instruct, and / or coach a user according to one or more features of the system. Advantageously, the system may improve adherence and facilitate patient engagement, care transition, and disease management, resulting in, for example, reduced healthcare costs for providers and payers, and enhanced drug use for pharmaceutical manufacturers, pharmacies, and specialty pharmacies.

A software program application that elicits, collects, corrects, and records patient responses to illness-diagnosis, prescribed medical-treatment, and anatomical and other relevant health-elements matching scenarios presented in crossword, scrolling matching, scrolling-capture, adventure-construction, adventure-capture, ballistic-target (shooter), and other video game formats, without-or-with virtual reality and without-or-with avatars is provided. Game application criteria for success may be based on diagnostic, prescribed medication / management, and optional anatomical or other related information that the application imports securely in compliance with HIPAA requirements from the Patient-Player's web health portal.

The invention provides an immortalized cell strain of human carotid globular paraganglioma, and in the SDHD gene, c.6Agt; the invention relates to a 178182delAAGGC (Alkali AAGGC). The invention also provides an immortalized cell strain of the human carotid artery globular paranglioma, and the preservation number of the immortalized cell strain is CGMCC (China General Microbiological Culture Collection Center) NO.45756. The invention also provides an application of the immortalized cell strain of the human carotid paraganglioma. The gene sequencing result of the immortalized cell line shows that the SDHD gene mutation site (EO3 exon c.178182delAAGGC) exists in the immortalized cell line. The tumor cell line is a cell strain derived from human carotid artery globular paraganglioma, and the discovery of the cell strain contributes to the basic research and drug therapy of the carotid artery globular paraganglioma at present.

A mobile computing device for providing medication therapy recommendations includes a secure execution environment having one or more services executing therein. One service of the one or more services is configured to establish a secure user interaction process at the mobile computing device. The mobile computing device includes a normal execution environment having a medication therapy application executing therein. The medication therapy application is configured to determine at least one medication delivery instruction, request confirmation of the delivery instruction using the secure user interaction process, and provide certified medication delivery instructions to a communications interface configured for communication with a medication delivery unit responsive to a confirmation result. The confirmation result is received, at least in part, responsive to the secure user interaction process.